Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
VTVT

VTVT - vTv Therapeutics Inc Stock Price, Fair Value and News

$33.28-0.43 (-1.28%)
Market Closed

9/100

VTVT

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

9/100

VTVT

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

VTVT Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

VTVT Price Action

Last 7 days

-6.0%

Last 30 days

-3.2%

Last 90 days

-3.9%

Trailing 12 Months

128.6%

VTVT RSI Chart

VTVT Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

VTVT Valuation

Market Cap

111.2M

Price/Earnings (Trailing)

-4.12

Price/Sales (Trailing)

109.31

EV/EBITDA

-0.72

Price/Free Cashflow

-4.4

VTVT Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

VTVT Fundamentals

VTVT Revenue

VTVT Earnings

Earnings (TTM)

-27.0M

Earnings Growth (Yr)

-96.42%

Earnings Growth (Qtr)

17.94%

VTVT Profitability

EBT Margin

-3056.05%

Return on Equity

-41.86%

Return on Assets

-30%

Free Cashflow Yield

-22.72%

VTVT Investor Care

Shares Dilution (1Y)

6.12%

Diluted EPS (TTM)

-2.99

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20250000
20241.6M1.4M1.2M1.0M
20230001.8M
20225.0M5.0M2.0M2.0M
20215.8M5.2M4.6M4.0M
20200006.4M
201911.3M10.6M7.3M2.8M
20182.3M4.8M8.1M12.4M
2017288.0K119.0K96.0K291.0K
2016845.0K917.0K822.0K634.0K
20151.3M1.0M776.5K519.0K
20141.1M1.3M1.4M1.5M
2013000976.0K
Get all data in R, Python etc through our Historical Stock Data APIs

About vTv Therapeutics Inc

VTVT
vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company's lead drug candidate is TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and psoriasis. It is also involved in the clinical development of other programs, including TTP273, an oral small molecule GLP-1 receptor agonist for postprandial glucose excursion to treat cystic fibrosis related diabetes; HPP3033, a non-electrophilic therapeutic approach to activating the Nrf2 pathway for the treatment of chronic diseases associated with oxidative stress; azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for pancreatic and breast cancers; and HPP971, an Nrf2 activator. vTv Therapeutics Inc. has a license agreement with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593; and license and research agreements with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.
 CEO
 WEBSITEhttps://vtvtherapeutics.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES13

vTv Therapeutics Inc Frequently Asked Questions

VTVT is the stock ticker symbol of vTv Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Mar 13 2026, market cap of vTv Therapeutics Inc is 111.17 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Fri Mar 13 2026, VTVT's PE ratio (Price to Earnings) is -4.12 and Price to Sales (PS) ratio is 109.31. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. VTVT PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, vTv Therapeutics Inc has provided -0.177 (multiply by 100 for percentage) rate of return.